Risk evaluation of non-metastatic but MYC-amplified group 3 tumors with an LCA histology or isochromosome i17q or group 4 MBs with anaplastic histology requires further clarifications [8] (Fig. 2a, 3a). The gene discussed is MYC; the disease is Mobius syndrome.